Biomarkers in cancer staging, prognosis and treatment selection

Nature Reviews Cancer

Volumn 5, Issue 11, 2005, Pages 845-856

  Ludwig, Joseph A ^a   Weinstein, John N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; BLADDER TUMOR ASSOCIATED ANTIGEN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRIN; FIBRIN DEGRADATION PRODUCT; MUCIN; NUCLEAR MATRIX PROTEIN 22; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; STEM CELL FACTOR; THYROGLOBULIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENOMICS; HUMAN; NONHUMAN; PAPANICOLAOU TEST; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; VALIDATION PROCESS;

ANIMALS; GENOMICS; HUMANS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 28544446695     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1739     Document Type: Review

References (145)

1. Sobin, L. H. TNM: evolution and relation to other prognostic factors. Semin. Surg. Oncol. 21, 3-7 (2003). Historical perspective of the TNM staging guidelines.
2. Hammond, M. E. & Taube, S. E. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 29, 213-221 (2002). Provides useful guidelines for the discovery, evaluation and validation of clinical biomarkers.
3. Negm, R. S., Verma, M. & Srivastava, S. The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8, 288-293 (2002).
4. US Department of Health & Human Services; US Food and Drug Administration. Challenge and Opportunity on the Critical Path of New Medical Products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (2004).
5. Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).
6. Nishizuka, S. et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243-5250 (2003). Clear demonstration that numerous genomic, proteomic and tissue-based arrays can be used in concert to distinguish between colon and ovarian carcinomas.
7. Leong, P. P. et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J. Natl Cancer Inst. 90, 972-977 (1998).
8. Califano, J. et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J. Natl Cancer Inst. 91, 599-604(1999).
9. Califano, J. et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res. 6, 347-352 (2000).
10. Ma, X. et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 100, 5974-5979 (2003).
11. Abulafia, O. & Sherer, D. M. Automated cervical cytology: meta-analyses of the performance of the PAPNET system. Obst. Gynecol. Surv. 54, 253-264 (1999).
12. Destounis, S. V. et al. Can computer-aided detection with double reading of screening mammograms help decrease the false-negative rate? Initial experience. Radiology 232, 578-584 (2004).
13. Awai, K. et al. Pulmonary nodules at chest CT: effect of computer-aided diagnosis on radiologists' detection performance. Radiology 230, 347-352 (2004).
14. Erickson, B. J. & Bartholmai, B. Computer-aided detection and diagnosis at the start of the third millennium. J. Digit. Imaging 15, 59-68 (2002).
15. American Joint Committee on Cancer & American Cancer Society. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (eds Greene, F. L. et al.) (Springer, New York, 2002). AJCC guidelines for cancer staging.
16. 3. Q. J. Nucl. Med. 47, 209-220 (2003).
17. Blankenberg, F. G. et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl Acad. Sci. USA 95, 6349-6354 (1998).
18. Kuge, Y. et al. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med. 45, 309-312 (2004).
19. Krohn, K. A. Evaluation of alternative approaches for imaging cellular growth. Q. J. Nucl. Med. 45, 174-178 (2001).
20. Kostakoglu, L., Agress, H. Jr & Goldsmith, S. J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23, 315-340 (2003).
21. Kostakoglu, L. & Goldsmith, S. J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J. Nucl. Med. 44, 224-239 (2003).
22. Britz-Cunningham, S. H. & Adelstein, S. J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med. 44, 1945-1961 (2003).
23. Agrawal, M. et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650-656 (2003).
24. Revillion, F., Bonneterre, J. & Peyrat, J. P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 34, 791-808 (1998).
25. Press, M. F et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 54, 5675-5682 (1994).
26. Singletary, S. E. et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20, 3628-3636 (2002).
27. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
28. Balmain, A., Gray, J. & Ponder, B. The genetics and genomics of cancer. Nature Genet. 33 (Suppl.), 238-244 (2003).
29. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
30. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). Evidence that subtle mutations in EGFR can affect the clinical response to gefitinib.
31. Kaneda, H. et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 46, 247-254 (2004).
32. Ravdin, P. M. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19, 980-991 (2001).
33. Relling, M. & Dervieux, T. Pharmacogenetics and cancer therapy. Nature Rev. Cancer 1, 99-108 (2001).
34. Lenz, H. J. The use and development of germline polymorphisms in clinical oncology. J. Clin. Oncol. 22, 2519-2521 (2004).
35. Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646-650 (1977).
36. Sidransky, D. Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210-219 (2002). In-depth review of diverse biomarkers undergoing clinical evaluation.
37. Kahn, H. J. et al. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res. Treat. 86, 237-247 (2004).
38. Stathopoulou, A. et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 9, 5145-5151 (2003).
39. Hoon, D. S. et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60, 2253-2257 (2000).
40. Muller, V. & Pantel, K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res. 6, 258-261 (2004).
41. Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448-456 (2004).
42. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152-8162 (2004).
43. Brennon, J. A. et al. Molecular assesment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429-435 (1995).
44. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
45. Nigro, J. M., et al. Mutations in the p53 gene occur in diverse tumor types. Nature 342, 705-708 (1989).
46. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
47. Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686-692 (1995).
48. Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994).
49. Jenuwein, T. & Allis, C. Translating the histone code. Science 293, 1074-1080 (2001).
50. Esteller, M., Corn, P. G., Baylin, S. B. & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229 (2001).
51. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996).
52. Frommer, M. et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual dna strands. Proc. Natl Acad. Sci. USA 89, 1827-1831 (1992).
53. Jeronimo, C. et al. Quantitation of GTSP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747-1752 (2001).
54. Rosas, S. L. et al. Promoter hypermethylation patterns of p16, o6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939-942 (2001).
55. Belinsky, S. A. et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891-11896 (1998).
56. Palmisano, W. A. et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5958 (2000).
57. Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332-339 (1999).
58. Ramirez, J. L. et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 193, 207-216 (2003).
59. Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371-375 (2002).
60. Valenzuela, M. T. et al. Assessing the use of p16INK4a promoter gene methylation in serum for detection of bladder cancer. Eur. Urol. 42, 622-630 (2002).
61. Nakayama, H. et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Intl J. Cancer 105, 491-493 (2003).
62. Yamaguchi, S., Asao, T., Nakamura, J. I., Ide, M. & Kuwano, H. High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett. 194, 99-105 (2003).
63. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl J. Med. 343, 1350-1354 (2000).
64. Weinstein, J. N. Pharmacogenomics - teaching old drugs new tricks. N. Engl. J. Med. 343, 1408-1409 (2000).
65. Esteller, M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17, 55-60 (2005).
66. Cheng, J. C. et al. Preferential response of cancer cells to zebularine. Cancer Cell 6, 151-158 (2004).
67. Piekarz, R. & Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10, 2289-2298 (2004).
68. Piekarz, R. L. et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103, 4636-4643 (2004).
69. Mischel, P. S., Cloughesy, T. F. & Nelson, S. F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Rev. Neurosci. 5, 782-792 (2004).
70. Gray, J. W. & Collins, C. Genome changes and gene expression in human solid tumors. Carcinogenesis 21, 443-452 (2000).
71. Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. Serial analysis of gene expression. Science 270, 484-487 (1995).
72. Weigl, B. H., Bardell, R. L. & Cabrera, C. R. Lab-on-a-chip for drug development. Adv. Drug. Deliv. Rev. 55, 349-377 (2003).
73. Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
74. Papin, J. A, Hunter, T., Palsson, B. O. & Subramaniam, S. Reconstruction of cellular signalling networks and analysis of their properties. Nature Rev. Mol. Cell Biol. 6, 99-111 (2005).
75. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov. 1, 683-695 (2002). Comprehensive review of clinical proteomic technologies and associated pattern-based protein markers.
76. Perou, C. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
77. Sorlie, T., Perou, C., Brown, P., Botstein, D. & Borresen-Dale, A. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
78. Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
79. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
80. van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
81. Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
82. Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).
83. Ramaswamy, S., Ross, K., Lander, E. & Golub, T. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49-54 (2003).
84. Rosell, R. et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318-1325 (2004).
85. Salonga, D. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327 (2000).
86. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000).
87. Carr, K. M., Bittner, M. & Trent, J. M. Gene-expression profiling in human cutaneous melanoma. Oncogene 22, 3076-3080 (2003).
88. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
89. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
90. Lossos, I. S. et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl Acad. Sci. USA 99, 8886-8891 (2002).
91. Garber, M. E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98, 13784-13789 (2001).
92. Best, C. J. et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn. Mol. Pathol. 12, 63-70 (2003).
93. Zou, T. T. et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21, 4855-4862 (2002).
94. Zhou, G. et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics 1, 117-124 (2002).
95. Nishizuka, S. et al. Proteomic profiling of the NCl-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100, 14229-14234 (2003).
96. Paweletz, C. P. et al. Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 20, 1981-1989 (2001).
97. Verma, M., Wright, G. L. Jr, Hanash, S. M., Gopal-Srivastava, R. & Srivastava, S. Proteomic approaches within the NCl early detection research network for the discovery and identification of cancer biomarkers. Ann. NY Acad. Sci. 945, 103-115 (2001).
98. Wulfkuhle, J. D., Liotta, L. A. & Petricoin, E. F. Proteomic applications for the early detection of cancer. Nature Rev. Cancer 3, 267-275 (2003).
99. Sano, T., Smith, C. L. & Cantor, C. R. Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258, 120-122 (1992).
100. Nam, J. M., Thaxton, C. S. & Mirkin, C. A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884-1886 (2003).
101. Service, R. F. American Chemical Society Meeting. Tiny transistors scout for cancer. Science 300, 242-243 (2003).
102. Seydel, C. Quantum dots get wet. Science 300, 80-81 (2003).
103. Wu, X. et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature Biotechnol. 21, 41-46 (2003).
104. Ben-Ari, E. T. Nanoscale quantum dots hold promise for cancer applications. J. Natl Cancer Inst. 95, 502-504 (2003).
105. Igor, M. et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nature Mater. 2, 630-638 (2003).
106. Wulfkuhle, J. D. et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 62, 6740-6749 (2002).
107. Wulfkuhle, J. D. et al. New approaches to proteomic analysis of breast cancer. Proteomics 1, 1205-1215 (2001).
108. Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84 (2002).
109. Patel, V., Leethanakul, C. & Gutkind, J. S. New approaches to the understanding of the molecular basis of oral cancer. Crit. Rev. Oral Biol. Med. 12, 55-63 (2001).
110. Ornstein, D. K. et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235-2242 (2000).
111. Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001).
112. Barker, P. E. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann. NY Acad. Sci. 983, 142-150 (2003).
113. Ransohoff, D. F. Rules of evidence for cancer molecular marker discovery and validation. Nature Rev. Cancer 4, 309-314 (2004). Effectively summarizes the problem of data overfitting in discovery-based research and the need for 'rules of evidence' to ensure clinical validity.
114. Gutman, S. Regulatory issues in tumor marker development. Semin. Oncol. 29, 294-300 (2002). Examines the regulatory environment surrounding biomarker approval by the FDA and CMS.
115. Taube, S. E. & Freiberg, G. P. Regulatory issues related to marker development. Urol. Oncol. 5, 214-216 (2000).
116. Hackett, J. L. & Lesko, L. J. Microarray data - the US FDA, industry and academia. Nature Biotechnol. 21, 742-743 (2003).
117. Mendelsohn, A. R. & Brent, R. Postgenomic protein analysis: the next bend in the river. Nature Biotechnol. 16, 520-521 (1998).
118. Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, R8-R17 (2004).
119. Einspahr, J. G. et al. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol. Biomarkers Prev. 6, 37-48 (1997).
120. Togashi, K. Ovarian cancer: the clinical role of US, CT, and MRI. Eur. Radiol. 13 (Suppl. 4), L87-L104 (2003).
121. Schlieman, M. G., Ho, H. S. & Bold, R. J. Utility of tumor markers in determining resectability of pancreatic cancer. Arch. Surg. 138, 951-956 (2003).
122. Depres-Brummer, P. et al. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 121, 419-422 (1995).
123. Duncan, J. L., Price, A. & Rogers, K. The use of CA15.3 as a serum tumour marker in breast carcinoma. Eur. J. Surg. Oncol 17, 16-19 (1991).
124. Gion, M. et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J. 7, 181-190 (2001).
125. Chang, B. L. et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Intl J. Cancer 106, 375-378 (2003).
126. Lee, S. G. et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett. 187, 53-60 (2002).
127. Petrij-Bosch, A. et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet. 17, 341-345 (1997).
128. Newman, B. et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279, 915-921 (1998).
129. Wu, X. et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl Cancer Inst. 94, 681-690 (2002).
130. Bonnen, P. E., Wang, P. J., Kimmel, M., Chakraborty, R. & Nelson, D. L. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res. 12, 1846-1853 (2002).
131. Johnson, G. & Todd, J. Haplotype tagging for the identification of common disease genes. Nature Genet. 29, 233-237 (2001).
132. Hoque, M. O., Lee, C. C., Cairns, P., Schoenberg, M. & Sidransky, D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 63, 2216-2222 (2003).
133. Janne, P. A. et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 23, 2716-2726 (2004).
134. Boshoff, C. et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Med. 1, 1274-1278 (1995).
135. To, E. W. H. et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin. Cancer Res. 9, 3254-3259 (2003).
136. Leung, S. F. et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98, 288-291 (2003).
137. Mueller, N. Overview: viral agents and cancer. Environ. Health Perspect. 103 (Suppl. 8), 259-261 (1995).
138. Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
139. Pellet, C. et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J. Invest. Dermatol. 117, 858-863 (2001).
140. Polyak, K. et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genet. 20, 291-293 (1998).
141. Bianchi, N. O., Bianchi, M. S. & Richard, S. M. Mitochondrial genome instability in human cancers. Mutat. Res. 488, 9-23 (2001).
142. Welter, C., Kovacs, G., Seitz, G. & Blin, N. Alteration of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer 1, 79-82 (1989).
143. Fliss, M. S. et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017-2019 (2000).
144. Weinstein, J. N. Fishing expeditions. Science 282, 628-629 (1998).
145. Weinstein, J. N. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr. Opin. Pharmacol. 2, 361-365 (2002).